Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986326 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Placebo, followed by BMS-986326 Dose A or Dose B | EXPERIMENTAL | - |
| BMS-986326 Dose A, followed by Placebo | EXPERIMENTAL | - |
| BMS-986326 Dose B, followed by Placebo | EXPERIMENTAL | - |
| Cohort A: BMS-986326 Dose 1 IV | EXPERIMENTAL | - |
| Cohort B: BMS-986326 Dose 2 IV | EXPERIMENTAL | - |
| Cohort C1: BMS-986326 Dose 3 IV | EXPERIMENTAL | - |
| Cohort C2: BMS-986326 Dose 3 SC | EXPERIMENTAL | - |
| Cohort D2: BMS-986326 Dose 4 SC | EXPERIMENTAL | - |
| Cohort E2: BMS-986326 Dose 3 SC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986326 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
| Placebo for BMS-986326 | OTHER | Specified dose on specified days |
Inclusion Criteria: * Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening * Documented history of inadequate response to treatment with topical medication for at least 4 weeks, unless topical treatments are otherwise medically inadvisable, or has required systemic th...
BMS-986326 is an investigational small molecule being developed by Bristol-Myers Squibb for inflammatory skin and autoimmune conditions. It has been studied in Phase 1 clinical trials in adults with atopic dermatitis and in adults with different forms of lupus. It is not an approved therapy and remains in clinical development.
BMS-986326 has been evaluated in clinical studies for atopic dermatitis and for different forms of lupus. Both are inflammatory conditions, and the trials were designed to assess safety, tolerability, drug levels, and drug effects in adults. No approved use has been established for BMS-986326.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is the developer of BMS-986326. The company sponsored the Phase 1 studies of the compound in atopic dermatitis and lupus.
BMS-986326 is in Phase 1 development. Two Phase 1 trials have been completed, one in atopic dermatitis and one in different forms of lupus. The drug is investigational and has not been approved by the FDA for any indication.
BMS-986326 has been studied in two completed Phase 1 trials. NCT06248814 evaluated safety, tolerability, drug levels, and drug effects in participants with atopic dermatitis across Czechia, France, Germany, Poland, and Spain. NCT06013995 studied the same endpoints in adults with different forms of lupus across the United States, Argentina, Bulgaria, Germany, Netherlands, Poland, Romania, and Spain.
The atopic dermatitis trial NCT06248814 enrolled 64 participants, and the lupus trial NCT06013995 enrolled 45 participants. Both were Phase 1, randomized, double-blind, controlled studies in adults aged 18 years and older, and both have been completed.